01324-6/asset/f8796f89-5117-40f3-b350-bca267093e71/main.assets/gr1.gif)
surpass 1 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Post Hoc Analysis of SURPASS-1
Description
Methods A randomised crossover trial was conducted in 22 healthy adults (age 24.63.1 years, BMI 23.12.7 kg/m2) receiving 25 g available carbohydrates from a -glucan-enriched oat bread or a control whole-wheat bread at two non-consecutive days
Personalized wellness treatments designed to support energy, longevity, and overall health.
2026, OBrien, Terrance
Apart from bariatric surgery, treatment options to decrease body weight are often underwhelming
What happened to Amino Asylum
Kentuckys Opioid Abatement Advisory Commission approved $3.6 million for a three-part addiction prevention campaign geared toward youth.
